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Abstract
Introduction: Normal and neoplastic breast tissues are comprised of heterogeneous populations of epithelial cells
exhibiting various degrees of maturation and differentiation. While cultured cell lines have been derived from both
normal and malignant tissues, it remains unclear to what extent they retain similar levels of differentiation and
heterogeneity as that found within breast tissues.
Methods: We used 12 reduction mammoplasty tissues, 15 primary breast cancer tissues, and 20 human breast
epithelial cell lines (16 cancer lines, 4 normal lines) to perform flow cytometry for CD44, CD24, epithelial cell
adhesion molecule (EpCAM), and CD49f expression, as well as immunohistochemistry, and in vivo tumor xenograft
formation studies to extensively analyze the molecular and cellular characteristics of breast epithelial cell lineages.
Results: Human breast tissues contain four distinguishable epithelial differentiation states (two luminal phenotypes
and two basal phenotypes) that differ on the basis of CD24, EpCAM and CD49f expression. Primary human breast
cancer tissues also contain these four cellular states, but in altered proportions compared to normal tissues. In
contrast, cultured cancer cell lines are enriched for rare basal and mesenchymal epithelial phenotypes, which are
normally present in small numbers within human tissues. Similarly, cultured normal human mammary epithelial cell
lines are enriched for rare basal and mesenchymal phenotypes that represent a minor fraction of cells within
reduction mammoplasty tissues. Furthermore, although normal human mammary epithelial cell lines exhibit
features of bi-potent progenitor cells they are unable to differentiate into mature luminal breast epithelial cells
under standard culture conditions.
Conclusions: As a group breast cancer cell lines represent the heterogeneity of human breast tumors, but
individually they exhibit increased lineage-restricted profiles that fall short of truly representing the intratumoral
heterogeneity of individual breast tumors. Additionally, normal human mammary epithelial cell lines fail to retain
much of the cellular diversity found in human breast tissues and are enriched for differentiation states that are a
minority in breast tissues, although they do exhibit features of bi-potent basal progenitor cells. These findings
suggest that collections of cell lines representing multiple cell types can be used to model the cellular
heterogeneity of tissues.
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Human breast cell lines have long served as models for
aw i d ea r r a yo fa p p l i c a t i o n si n c l u d i n gt h es t u d yo f
molecular, cellular, and biochemical mechanisms that
regulate breast epithelial biology. Breast cancer cell lines
are also commonly used in xenograft models for drug
discovery and in the assessment of pre-clinical experi-
mental therapeutic efficacy. Despite their crucial role for
rational drug discovery and development and in under-
standing molecular pathophysiology of cancer, their
ability to accurately reflect phenotypes of tumors
remains controversial. Several studies have suggested
that cell lines exhibit a narrow range of genetic profiles,
harbor genetic alterations due to adaptation of tissue
culture environment, and are poor predictors of in vivo
sensitivity to drug efficacy [1-3]. Cell line-derived xeno-
graft models also fail to recapitulate the heterogeneous
histopathology characteristic of the parent tumor histol-
ogy. However, other studies have indicated that cell
lines, as a system, actually mirror many of the biological
and genomic properties found within primary human
tumors [4,5]. Genomic approaches have revealed that
like primary tumors, the gene expression signatures of
breast cancer cell lines can distinguish luminal from
basal subtypes of breast cancer [6-9]. Moreover, cell
line-derived gene signatures can correctly classify
human tumor samples [6,7,10], suggesting that despite
their acquired ability to grow in vitro, and acquired
mutations following adaptation to culture conditions,
cell lines continue to share many of the molecular and
genetic features of the primary breast cancers from
which they were derived.
The use of primary human breast tissues for experi-
mental studies and breast cancer research has been
fueled by the notion that cell lines are not accurate
models of the heterogeneity found in vivo.A ss u c h ,
reduction mammoplasty and cancer tissues have been
used to identify and characterize epithelial differentia-
tion states and lineages since it is presumed that not all
cell types are maintained or mirrored in vitro.E x p r e s -
sion of epithelial cell adhesion molecule (EpCAM) and
CD49f
+ (a6 integrin) have been used to identify luminal
and basal/myoepithelial cells from breast tissues [11-14].
Mature luminal cells are reported to express an
EpCAM
+/CD49f
- phenotype while luminal progenitors
express an EpCAM
+/CD49f
+ marker profile. Myoepithe-
lial cells and basal progenitor cells are defined by an
EpCAM
-/CD49f
+ phenotype [11,13,15]. In addition to
EpCAM and CD49f, surface expression of CD44 and
CD24 have also been used to identify luminal epithelial
cells that express genes involved in hormone responses
(CD24
+) and cells resembling progenitor cells that
express genes involved in motility (CD44
+) [16].
Reflecting the normal cell types within the breast,
tumors are broadly classified histopathologically by
expression of either luminal cytokeratins (CK8/18) or
stratified epithelial cytokeratins (CK5/6/14, basal-type)
[17,18]. Similarly, tumor subclasses identified by micro-
array were named to reflect the gene expression patterns
of the normal breast luminal and myoepithelial/basal
cells [19-23]. Luminal-type breast cancers (Luminal A
and Luminal B) express estrogen receptor (ER). Her2-
type breast cancers typically overexpress or amplify
Her2, are generally negative for ER expression and tend
to express the genes associated with the Her2-amplicon.
Lastly, Basal-like breast cancers are also often referred
to as triple-negative tumorss i n c et h e yd on o te x p r e s s
ER, progesterone receptor (PR), or Her2 [19-22].
To determine if cell lines mirror or maintain the cellu-
lar differentiation states found in primary tissues, we
examined the molecular and cellular profiles of normal
and malignant human breast epithelial cell lines and
compared them to normal and cancerous tissues. In
doing so, we found four distinguishable cell states across
a collection of cell lines that mirrored the four differen-
tiation states present within normal and malignant
breast tissues. However, we also found that the cellular
heterogeneity within cell lines was remarkably restricted
in culture and was enriched for cellular phenotypes that
were normally present as a minor component in vivo.
Materials and methods
Cell lines and tissue culture
SUM cell lines were obtained from Dr. Stephen Ethier
(Kramanos Institute, Detroit, MI, USA) and are com-
mercially available (Asterand, Detroit, MI, USA). The
MCF7, T47 D, BT20, MCF10A, MCF10F, MDA.MB.231,
MDA.MB.361 and HCC cell lines were obtained directly
from the American Type Culture Collection (ATCC;
Manassas, VA, USA). The MCF10A and MCF10F cell
lines are non-tumorigenic mammary epithelial cell lines
that were produced by long-term culture in serum-free
medium with low calcium; the MCF10A cells were
derived from an the adherent population in these cul-
tures, while the MCF10F line was derived from floating
cells within the MCF10 cultures [24]. All of the ATCC
cell lines used in this study were low passage (< 10).
SUM225CWR, SUM149PT, and SUM159PT cells were
cultured in F12 with 5% calf serum (CS), insulin (5 μg/
ml), and hydrocortisone (1 μg/ml), while SUM1315
MO2 cells were cultured in F12 with 5% CS, insulin (5
μg/ml), and hEGF (10 ng/ml). MCF7, MDA.MB.361,
BT20, and all HCC cell lines were cultured in DMEM
with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad,
CA, USA). MDA.MB.231 and T47 D cells were cultured
in Roswell Park Memorial Institute-1640 (RPMI;
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breast cancer cell line was established from a primary
invasive ER-positive adenocarcinoma. An ER-negative
cancer cell line spontaneously emerged after two
months of cultivations. TUM177 cells were cultured in
DMEM with 10% fetal bovine serum (FBS; Invitrogen,
Carlsbad, CA, USA).
HME I and HME II cells were derived from reduction
mammoplasty tissues from two different patients grown
in Mammary Epithelial Growth Medium (MEGM) until
the generation of variant cells [25] and then immorta-
lized through the ectopic expression of the catalytic sub-
unit of human telomerase (hTERT) [26].
MCF10F cells were cultured in Dulbecco’s modified
Eagle’sm e d i u m - H a m ’s F12 (DMEM/F12; 1:1) with 5%
horse serum, insulin (5 μg/ml), hydrocortisone (1 μg/
ml), and human epidermal growth factor (hEGF; 10 ng/
ml), and cholera toxin (100 ng/ml) (all, Sigma, St. Louis,
MO, USA). MCF10A and immortalized human mam-
mary epithelial (HME) cell lines were cultured in
MEGM supplemented with bovine pituitary extract (52
μg/ml), hydrocortisone (0.5 μg/ml), hEGF (10 ng/ml)
and insulin (5 μg/ml) (MEGM Bullet Kit, Lonza Cor-
p o r a t i o n ,W a l k e r s v i l l e ,M D ,U S A ) .M C F 1 0 Ac e l l sw e r e
further supplemented with cholera toxin (100 ng/ml).
For serum differentiation experiments, HME or
MCF10A cells were switched to growth in the MCF10F
medium with substitution of 5% CS for the horse serum
and omission of the cholera toxin, or 5% CS was added
to MEGM and cells were allowed to differentiate for six
days before use in experiments. For mammosphere cul-
ture, cells were plated at 20,000 cells/ml and grown on
ultra-low adherence six-well plates for one week (Corn-
ing Life Sciences, Lowell, MA, USA). Quantification of
mammospheres was accomplished using a Multisizer 3
COULTER COUNTER (Beckman-Coulter, Brea, CA
USA) that provides number, and size distributions with
an overall sizing range of 14 μm to 336 μm.
Reduction mammoplasty and tumor tissue specimens
All human breast tissue procurement for these experi-
ments was obtained in compliance with the laws and
institutional guidelines, as approved by the Institutional
Review Board committee from Beth Israel Deaconess
Hospital and Tufts Medical Center. Fresh disease-free
reduction mammoplasty tissues (n = 12) and tumor tis-
sues (n = 15; 8 fresh, 15 formalin-fixed paraffin
embedded) were obtained from discarded material from
patients undergoing elective reduction mammoplasty
surgeries or from patients undergoing partial or com-
plete mastectomy for excision of tumor tissue from the
Pathology departments at BIDMC or Tufts Medical
Center. All samples were obtained from de-identified
discarded material and therefore, informed consent was
not required for these studies. All samples were evalu-
ated histologcially and confirmed to be invasive ductal
carcinomas. The following histopathologic variables,
determined for all tumor tissue specimens, were done
on full sections, and cases with 10% or more positive for
ER, p53 or EGFR staining were grouped as positive. The
scoring of Her2 was performed using the ASCO/CAP
guidelines, as follows: Cases with 30% or more strongly
positive cells with strong complete membrane staining
were defined as Her2+ tumors. Cases with 10% or more
positive cells with weak to moderate complete mem-
brane staining were considered Her2+ but were not
defined as Her2+ tumors solely on this basis. IHC analy-
sis for estrogen receptor (ER), progesterone receptor
(PR), Her2, p53 and EGFR were independently reviewed
by expert breast pathologists (HG and SN). Breast
tumor subtypes were defined as follows: Luminal A
(ER+ and/or PR+, Her2-), Luminal B (ER+ and/or PR+,
Her2+), Her2+ (ER-, PR-, Her2+), and Basal-like (ER-,
PR-, Her2-, and epidermal growth factor receptor
(EGFR)+/-) and p53+.
Uncultured cells from reduction mammoplasty or
human breast tumor organoid preps [27] were disso-
ciated to a single-cell suspension by trypsinization and
filtered through a 20 μm nylon mesh (Millipore, Dan-
vers, MA, USA). Human breast tumors were plated in
DMEM supplemented with 10% CS for one to two
hours to deplete stromal cells.
Immunohistochemical analysis and scoring
Immunohistochemistry was performed by the Histology
Special Procedures Laboratory at Tufts Medical Center
on paraffin-embedded tissue sections on a Ventana
(Tucson, Arizona, USA) automated slide stainer with
the iVIEW DAB detection kit for visualization. Antibo-
dies used were CK14 (1:500, clone LL002, Vector (Bur-
lingame, CA, USA)), CK8/18 1:500, clone DC-10,
Vector), Vimentin (1:500, clone V9, Vector), S100A4
(1:200, clone 1F12-1G7, Sigma), S100A6 (1:200, clone
CACY-100, Sigma), p53 (Ventana Medical Systems), ER
(Ventana Medical Systems), Her2 (Ventana Medical Sys-
tems), EGFR (1:20, clone 31G7, Zymed), and PR (Ven-
tana Medical Systems). All Ventana antibodies are
prediluted.
IHC and IF results were semi-quantitatively analyzed
in a blinded fashion across multiple patient samples
using a scoring metric in 10% increments. Negative
staining represents 0 to 10% of the cell staining and was
given a score of 1; mixed staining represents moderate
to strong intensity staining of cells with > 10% but
< 50% positive cells and was given a score of 2; and
positive staining represents strong intense staining with
> 50% cells staining positive and was given a score of 3.
The staining intensity and percent staining scores were
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average total stain score was calculated for the staining
for a particular sample. Statistical analysis was per-
formed using the student’s t-test across the different
patient samples.
Flow cytometry and FACS
Uncultured cells from reduction mammoplasty tissues
(n = 12) or primary breast tumor tissues (n = 8) from
organoid preparations were dissociated to single-cell
suspensions, as described above. For reduction mammo-
plasty tissues, endothelial, lymphocytic, monocytic, and
fibroblastic lineages were depleted with antibodies to
CD31, CD34 and CD45 (all Thermo/LabVision, Fre-
mont, CA, USA) and Fibroblast Specific Protein/IB10
(Sigma) using a cocktail of Pan-mouse IgG and IgM
Dynabeads (Dynal, Invitrogen) according to the manu-
facturers instructions and as described previously [28].
Depleted single cells suspensions were resuspended at 1
×1 0
6 cells/ml in phosphate-buffered saline containing
1% calf serum (FACS buffer, FB) and bound with fluor-
escently-conjugated antibodies to human EpCAM
(APC), CD49f (PE), and CD24 (FITC) (all, BD Bios-
ciences, San Jose, CA, USA) for 20 minutes at 4°C. Anti-
body-bound cells were washed and resuspended at 1 ×
10
6 cells/ml in FB and run on a FACSCalibur flow cyt-
ometer. Flow cytometry data was analyzed with the
Flowjo software package (TreeStar, Ashland, OR, USA).
For fluorescence-activated cell sorting (FACS), cells
from reduction mammoplasty tissue were prepared as
above for flow cytometry and resuspended at 5 x10
6
cells/ml in FB and sorted on a BD Influx Cell sorter
(BD Biosciences) into culture medium (MEGM) con-
taining 50% CS.
For cell lines, non-confluent cultures of cells were
trypsinized into single cell suspension, counted, washed
with PBS, and stained with antibodies specific for
human cell CD24 (PE) and CD44 (APC) (BD Bios-
ciences). The cells were stained with antibodies specific
for human cell surface markers: EpCAM-fluorescein iso-
thiocyanate (FITC), CD24-phycoerythrin (PE), and
CD49f-PE-Cy5 or CD44-allophycocyanin (APC) (BD
Biosciences). Additional cells were stained with isotype
controls for each antibody: Ms IgG1-FITC, Ms IgG2a-PE,
and Rat IgG2a-PE-Cy5 or Ms IgG2b-APC (BD Bio-
sciences). A total of 200,000 to 800,000 cells were incu-
bated with antibodies or isotype controls for 20 minutes
on ice. The cells were washed with PBS to remove any
unbound antibody and analyzed no later than one hour
post-staining on a FACSCalibur flow cytometer (BD
Biosciences). Antibody-bound cells were resuspended at
1×1 0
6 c e l l s / m li nF Ba n dr u no naF A C S C a l i b u rf l o w
cytometer (BD Biosciences) or sorted on an BD Influx
FACS sorter (BD Biosciences). Flow cytometry data was
analyzed with the Flowjo software package (TreeStar).
Each cell line was analyzed in three to five different bio-
logical replicates.
Immunofluorescence
Collected cell fractions from FACS were counted and
cytospun onto glass slides at 10,000 cells per spot with a
Cytospin 4 cytospinner (Thermo Scientific, Waltham,
MA, USA). Cultured cell lines were plated at 10 to
20,000 cells per well in eight-well chamber slides (BD
Biosciences) and grown two to three days. Cytospins
and cells in chamber slides were fixed in 100% methanol
and stained overnight at 4°C with primary antibodies
directed to EpCAM (VU-ID9, 1:100, Stem Cell Technol-
ogies, Vancouver, BC, Canada), CK8/18 (5D3, 1:500,
Vector Labs, Burlingame, CA, USA), ERa (1D5, 1:100,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) CK14
(ASM-1, 1:500, Thermo Scientific/LabVision), a-smooth
muscle actin (SMA; 1:250, Vector Labs) and vimentin
(V9, 1:500, Vector Labs) followed by secondary antibo-
dies (1:500 Alexa488 or Alexa555 conjugated anti-
mouse and anti-rabbit H+L IgG, Invitrogen) for one
hour at room temperature. Nuclei were counterstained
with 4’, 6-diamidino-2-phenylindole (DAPI) and images
were captured with the Spot imaging software (Diagnos-
tic Instruments, Inc., Sterling Heights, MI, USA); stain-
ing was analyzed by counting the total number of cells
positive stain compared to the total number of cells in
multiple fields with at least 50 cells analyzed per condi-
tion. Negative staining represents no cells staining posi-
tive, Mixed staining is > 1% but < 50% of the cells
staining positive, while positive staning is > 80% of the
cells staining positive.
An average total stain score of a cell line was calcu-
lated using three to five different regions of the plate.
Statistical analysis was performed using the student’sT -
test across the different patient samples.
Animals and surgery
All animal procedures were performed in accordance
with an approved protocol submitted to the Tufts Uni-
versity Institutional Animal Care and Use Committee. A
colony of NOD/SCID mice was maintained under sterile
conditions and received food and water ad libum. Nulli-
parous female mice aged 8 to 10 weeks were utilized in
all experiments. For tumor latency studies, 1 × 10
6
human breast cancer cells were resuspended in media
and Matrigel (1:1; BD Biosciences) and injected orthoto-
pically in a total of 4 to 10 different glands. Tumor for-
mation was assessed by palpitation at least once a week,
and tumor growth curves were calculated from weekly
caliper measurements as previously described. Tumor
latency is described as the time it takes for a tumor to
reach a diameter of 1 cm.
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Fisher exact tests were used when comparing the binary
categories of expression of proteins between groups. All
P-values reported are two-sided.
Results
CD44 and CD24 expression in human breast cancer cell
lines
Studies have suggested that the pre-existing differentia-
tion state of normal precursor cell types is so strongly
encoded it survives the neoplastic transformation and
accounts in part for tumor phenotype [29,30]. Based on
this notion, we reasoned that it might be possible to
map different tumor subtypes to their normal cellular
precursors within human breast tissues based on the
expression of cell surface markers. Recently, the cell sur-
face markers CD24 and CD44 have been used to define
normal human breast epithelial differentiation states:
CD44 is expressed in basal cells while CD24 is
expressed in luminal cells [16].
We wanted to determine whether these markers could
be used to classify luminal and basal breast cancer cell
lines, many of which have been previously classified on the
basis of gene expression profiling [7,31]. Using a panel of
16 cancer lines we found that all breast cancer cell lines
contained a population of CD44
+ cells regardless of tumor
subtype. Most of the lines (11/16) contained a majority (>
80%) of CD44
+ cells, while the remaining cell lines (5/16)
contained a minority (< 40%) of CD44
+ cells (Figure 1a,
Additional files 1 and 2). There was no correlation (P =
0.14, P = 0.44, P = 1) between the proportion of CD44
+
(greater than or 80% or less than 40%) cells within the cell
line with breast cancer subtype.
In contrast to CD44 expression, not all breast cancer cell
lines contained CD24
+ cells. Rather, 10/16 lines contained
a large proportion (> 70%) of CD24
+ cells, while 6/16 lines
contained very few (< 5 to 45%) CD24
+ cells (Figure 1b,
Additional files 1 and 2). As with CD44 expression, there
was no correlation between the proportion of CD24
+ cells
in cell lines and tumor subtype. Since CD44 and CD24
expression alone could not be used to classify cell lines
based on tumor subtype, we examined whether together
these markers might be able to categorize cell lines. While,
the proportion of CD44
+/CD24
- cells did not correlate
with gene expression-based classifiers of breast cancer
subtype, consistent with previous reports, there was a
striking relationship between the proportion of CD44
+/
CD24
- cells in the line and spindle-cell morphology
(Figure 1c), [32,33] (Additional files 1, 2, 3 and 4).
EpCAM, CD24 and CD49 expression reduction
mammoplasty tissues
Since CD44 and CD24 were not useful markers to clas-
sify tumor cells, we wanted to determine whether
additional lineage markers might be able to refine cellu-
lar differentiation states. Accordingly, we used flow cyto-
metry to characterize breast epithelial cells from
reduction mammoplasty tissues (n = 12) using EpCAM,
and CD49f expression. EpCAM and CD49f have been
used previously to define cells within the luminal and
basal lineages from normal human breast tissue
[11,14,15].
We identified four epithelial cell populations (two
populations of luminal cells and two populations of
basal cells) from freshly dissociated, lineage-depleted
breast epithelial cells from reduction mammoplasty tis-
sues on the basis of EpCAM/CD24/CD49f expression
(Figure 2). There were three populations of cells identi-
fied on the basis of EpCAM expression; EpCAM
hi cells,
which expressed CD24 but were either CD49f
+ or
CD49f
-,E p C A M
low cells that lacked CD24 expression
but expressed CD49f, and EpCAM-negative cells that
also lacked CD24 expression but were CD49f-positive.
To confirm the nature of these cell types, we sorted
lineage-depleted cells from reduction mammoplasty tis-
sues by FACS, and cytospun freshly sorted cells to
examine the expression of established markers of lumi-
nal and myoepithelial/basal cells (Figure 2b, c). Highly
expressing EpCAM
+ luminal cells were either CD49f
+ or
CD49f
-, consistent with the definition of mature luminal
cells and luminal progenitor cells, respectively [14,15].
EpCAM
+/CD49f
- and EpCAM
+/CD49f
+ cells were pre-
dominantly CK8/18 positive, lacked CK14 and SMA
expression thus were termed Luminal 1 and Luminal 2
cells, respectively. EpCAM
+/CD49f
- and EpCAM
+/CD49f
+ cells also both expressed CD24. However,
unlike previous reports, we observed a second EpCAM
+/CD49f
+ population of cells that expressed lower levels
of EpCAM. Unlike EpCAM
+/CD49f
+ luminal progenitor
cells, this population of EpCAM
+/CD49f
+ cells lacked
CD24 expression. In addition, EpCAM
+/CD24
-/CD49f
+
cells were predominantly CK14-positive, while EpCAM
+/CD24
+/CD49f
+ cells were predominantly CK18-postive
(Figure 2). Furthermore, EpCAM
+/CD24
-/CD49f
+ cells
expressed SMA and vimentin; and thus were termed
Basal. Finally, an EpCAM-negative population which
lacked CD24 expression was also identified. This popu-
lation expressed CD49f, expressed lower levels of CK14,
and strong levels of vimentin (Figure 2b, c). Although
EpCAM
-/CD49f
+ cells expressed basal epithelial mar-
kers, they were termed mesenchymal, due to the lack of
luminal epithelial markers (CD24 and EpCAM), and the
higher levels of vimentin expression.
Cellular and molecular heterogeneity in breast cancer
tissues
To determine whether these four epithelial cell types
were also present within breast cancer tissues, we
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primary human breast cancers (n = 8) by flow cytome-
try. Primary tumor tissues, in general, showed a different
spectrum of cellular heterogeneity compared to breast
reduction mammoplasty tissue by flow cytometry when
stained for EpCAM, CD49f, and CD24 (Figure 3a).
Although the four major cell types were still present
regardless of the tumor classification (Luminal (A or B),
Her2, Basal), several tumor tissues contained a larger
proportion of EpCAM
-/CD49f
+ Mesenchymal cells com-
pared to reduction mammoplasty tissues. Although the
number of tumors analyzed was too small to make any
Figure 1 CD44 or CD24 expression alone does not classify breast cancer cell lines into tumor subytpes. Breast cancer cell lines are
grouped based on tumor subtype classification defined by [7] as Luminal, Basal A (Bas A), Basal B (Bas B), or those that have not been
previously classified (NC). The percentage of cells in breast cancer cell lines expressing either CD44 (a) or CD24 (b) is variable and does not
correlate with tumor classification. (c) The percentage of cells in cancer cell lines expressing the CD44
+/CD24
- phenotype correlates with spindle/
mesenchymal features, not tumor subtype. Surface marker expression was quantified by flow cytometry (mean ± S.E.) as described in Materials
and methods. Phase contrast, bright-field photomicrographs of representative cell lines exhibiting epithelial versus spindle morphology.
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reduction mammoplasty can be divided into four epithelial differentiation states. Primary breast epithelial cells (n = 12) were isolated, lineage
depleted, stained with EpCAM, CD24, and CD49f, and quantified as described in Materials and methods. Representative dot plots of EpCAM vs.
CD49f staining (left) and CD24 vs. CD49f staining in EpCAM/CD49f populations (middle) are shown. Quantification of CD24 staining in Luminal 1/
2, Basal and Mesenchymal populations from 12 patient samples (right, mean ± S.E.). Quantification of immunofluorescence from a representative
patient sample is shown (% of total DAPI stained cells, minimum 50 cells analyzed). Luminal 1 and Luminal 2 cells from reduction mammoplasty
tissue are predominantly CK 8/18 positive. Basal and Mesenchymal cells expressed CK14, VIM, and aSMA. (b) Freshly dissociated epithelial cells
from reduction mammoplasty tissue were stained for EpCAM and CD49f expression, sorted by FACS and cytospun on onto slides for
characterization of lineage markers by immunofluorescence. Cytokeratin (CK) 18, 14, smooth muscle actin (aSMA) and vimentin (VIM)
immunofluorescence staining and quantification of sorted populations indicates luminal and basal/myoepithelial cell enrichment.
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similar cellular heterogeneity to normal reduction mammoplasty tissues when examined by flow cytometry using the markers EpCAM, CD24,
and CD49f as described in Materials and methods. (a) Representative flow cytometry dot plots of EpCAM and CD49f expression in reduction
mammoplasty tissues (RM) and primary human breast tumors of different subtypes. Quantification of flow cytometry tumors (n = 8) classified
clinically by expression of ER, PR and Her2 expression. (b) Primary breast cancers demonstrated heterogeneous expression of markers used to
characterize cancer cell line xenografts by immunohistochemistry as in Figure 2. Bar = 100 μm.
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note that basal tumors, which have been considered to
express mesenchymal markers, contained the fewest
numbers of EpCAM
-/CD49f
+ Mesenchymal cells, while
Her2-positive tumors, which are traditionally viewed as
a subset of luminal tumors, retained the fewest numbers
of EpCAM
+/CD49f
- Luminal 1 cells. It will be interest-
ing to determine if these observations can be expanded
across a wider spectrum of tumor specimens.
We also analyzed breast cancer tissues (n = 15) by
immunohistochemistry for markers of Luminal 1, Lumi-
nal 2, Basal and Mesenchymal cells. Consistent with the
flow cytometry data, human breast cancers exhibited
heterogeneous and variable expression of markers of
Luminal 1, Luminal 2, Basala n dM e s e n c h y m a lc e l l s ,
regardless of tumor subtype (Figure 3b). Future prospec-
tive studies are needed to determine whether the differ-
ences in cell state proportions within tumors are
associated with clinical and prognostic information.
EpCAM, CD24 and CD49 epithelial subtypes in breast
cancer cell lines
All 16 breast cancer cell lines were analyzed for the
expression of EpCAM, CD24, and CD49f to determine
whether the same four differentiation states present
within human breast tissues were retained in cultured
lines. While we indeed observed the presence of all four
of these differentiation states within the panel of human
breast cancer cell lines, the majority of cell lines failed
to retain Luminal 1 EpCAM
+/CD49f
- cells. Rather only
one class of cell lines could be readily distinguished
from all other lines by retaining this population of
EpCAM
+/CD24
+/CD49f
- cells (Figure 4a, Additional
files 4, 5 and 6); these cell lines are thereafter referred
to as Luminal 1-type lines. Luminal 1 cell lines were
derived from pleural effusions, and are strongly ER-posi-
tive, thus of the luminal subtype. A second class of cell
lines were distinguished by a prominent population (>
90%) of EpCAM
+/CD24
+/CD49f
+ luminal cells and are
thus referred to as Luminal 2 lines (Figure 4a, Addi-
tional files 4 and 5). Luminal 2 cell lines (6/16) included
cell lines that were derived from either pleural effusions
or primary tumor tissues and express ER, Her2 or both
ER and Her2 (Figure 4a, Additional files 4 and 6). The
third class of cell lines could be distinguished by two
prominent populations (> 15%) of EpCAM
+/CD49f
+
cells: EpCAM
+/CD24
+/CD49f
+ luminal cells and
EpCAM
+/CD24
-/CD49f
+ basal cells, the latter of which
were rare or absent in other cell lines. Thus, these can-
cer lines were referred to as Basal lines (Figure 4a, Addi-
tional files 4 and 6). All Basal cell lines (4/16) in this
category were derived from primary breast tumors and
are ER-, PR-, and Her2-negative. Finally, cell lines that
exhibited a spindle-like morphology in culture, were
derived from either pleural effusions or primary tumor
tissues and were largely comprised of EpCAM
-/CD24
-/
CD49f
+ Mesenchymal cells (> 90%) (Figure 4a, Addi-
tional files 4 and 6); thus, referred to as Mesenchymal
lines. Notably, all Mesenchymal cell lines lack ER, PR
and Her2 expression.
Consistent with previous reports, we observed a strong
association between the cell surface-based categories,
morphology and molecular markers. Luminal cells
(Luminal 1 and 2) grew as epithelial-differentiated
monolayers with tight cell-cell junctions. They all
expressed CK8/18 and EpCAM, and all lacked expres-
sion of the basal cytokeratin CK14 and mesenchymal
vimentin (Figure 4b, Additional files 4 and 6). In con-
trast, Mesenchymal cells appeared less differentiated and
exhibited a spindle-like appearance. They lacked expres-
sion of both of CK8/18 and CK14 expression and were
all strongly positive for vimentin expression (Figure 4b,
Additional files 4 and 6). Interestingly, Basal cell lines
generally exhibited a more scattered morphology com-
pared to Luminal cell lines but were more epithelial
compared to Mesenchymal cell lines. Consistent with
their luminal-like morphology, Basal cell lines all
expressed CK8/18 and EpCAM, but they all also
expressed the basal maker CK14 (Figure 4b, Additional
files 4 and 6), which was absent in both Luminal and
Mesenchymal cell lines. Moreover, vimentin expression
was rarely detected in Basal lines and when it was, it
was focal and restricted to rare cells within the popula-
tion (Additional files 4 and 6). These findings indicate
that breast cancer cell lines retain the four cell differen-
tiation states that map to normal precursors found in
reduction mammoplasty tissues.
In vivo tumorigenicity and growth characteristics of
human breast cancer cell lines
We injected all 16 breast cancer cell lines into immuno-
deficient NOD/SCID mice and assessed each line for
tumor formation, invasiveness and histopathology of the
xenografts (Figure 5). Xenograft tumors that developed
from adherent cancer cell lines were all poorly differen-
tiated, high grade carcinomas. Despite the lack of differ-
entiation, the cell line definition did correlate with
morphologic features and the expression of established
biomarkers within the tumors (Figure 5b, Additional file
6). Luminal 1, Luminal 2, and Basal cancer cell lines all
formed solid epithelial carcinomas in mice, some of
which exhibited both invasive and in situ ductal or
comedo-like growth patterns, or squamous differentia-
tion features. In contrast, Mesenchymal cell lines formed
solid carcinomas that lacked obvious ductal features and
exhibited metaplastic and/or carcino-sarcoma differen-
tiation (Figure 5b, Additional files 6 and 7). Luminal 1
cell lines formed tumors that were exclusively
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Page 9 of 17Figure 4 Surface markers EpCAM, CD24, and CD49f classify breast cancer cell lines into distinct differentiation states. (a) Cell surface
markers EpCAM, CD24, and CD49f distinguish four classes of cell lines that map to differentiation states found in normal precursor cells. Surface
marker expression was quantified by flow cytometry (mean ± S.D., n = 3 to 4 biological replicates per cell line) as described in Materials and
Methods. (b) Luminal 1, Luminal 2, Basal, and Mesenchymal cell lines identified by EpCAM, CD24, and CD49f expression were classified on the
basis of CK14, CK8/18, ERa, EpCAM, and vimentin expression. Representative immunofluorescence images are shown from MCF7 (Luminal 1),
BT20 (Luminal 2), HCC1806 (Basal), and MDA.MB.231 (Mesenchymal). Nuclei were counterstained with DAPI (blue). ER expression of Luminal II
cells is heterogeneous across cell lines. Cell lines T47 D, HCC1500, and MDA.MB.361 all express ER (MDA.MB.361 is shown in inset), while BT20,
SUM225 and HCC1419 are ER-negative. Original magnification: 200×. Bar = 100 μm.
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Page 10 of 17Figure 5 Cell line marker profiles correlate with established biomarkers in tumor xenografts. (a) Tumor growth curves of cell line-derived
xenografts over time. Tumorigenicity of breast cancer cell lines was not correlated with their individual cellular profiles when injected into
mammary glands of NOD/SCID mice. (b) Cell line marker profile correlated with resulting tumor histology and expression of biomarkers.
Representative H&E stained sections of tumor xenografts from Luminal 1 and 2 cell lines (MCF7, SUM225) showing intraductal and comedo-like
DCIS patterns of growth respectively, as well as, Basal cell line (HCC1806) showing solid carcinoma growth with squamous differentiation, and
Mesenchymal cell lines (SUM159) showing spindle-cell metaplastic-like growth. Original magnification: 100×. Immunohistochemistry was used to
stain tumor xenografts for expression of ERa, Her2, p53, CK14, CK18 and vimentin. Representative images shown from tumors of Luminal 1
(MCF7), Luminal 2 (MDA.MB.361), Basal (SUM 149), and Mesenchymal (MDA.MB.231) cell lines. Bar = 100 μm.
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Page 11 of 17ER-positive and negative for p53, vimentin and Her2.
Luminal 2 cell lines also formed tumors that expressed
either ER and/or Her2, but failed to express p53 or
vimentin (Figure 5b, Additional files 6 and 7). Basal cell
l i n e sf o r m e dt u m o r st h a te x p r e s s e dr o b u s tp 5 3b u t
lacked ER and Her2 expression (Figure 5b, Additional
files 6 and 7). Basal tumors also lacked vimentin expres-
sion with the exception of the tumor-stromal interface
(data not shown). Unlike Luminal and Basal cell lines,
Mesenchymal cancer cell lines formed almost exclusively
spindle-cell metaplastic tumors that lacked obvious
epithelial features (Figure 5b, Additional files 6 and 7).
In addition, tumors derived from Mesenchymal lines
were strongly and uniformly positive for vimentin and
p53, consistent with clinical basal-like tumors (Figure
4b, Additional files 6 and 7). However, unlike primary
human basal-like breast cancers that have been reported
to express EGFR protein, EGFR expression in cell-line
derived xenograft tumors waso n l yw e a k l ye x p r e s s e di n
HCC1806 and TUM177 xenografts and not expressed
preferentially in tumors derived from other Basal or
Mesenchymal cell lines despite its expression in these
cultured cell lines (Additional files 6 and 7, and [10]).
Enrichment for basal phenotypes in normal breast cell
lines
Since the majority of breast cancer cell lines failed
to maintain EpCAM
+/CD24
+/CD49f
- Luminal 1 cells
in vitro, we wanted to determine whether this was a
general feature of in vitro cell cultivation or was a con-
sequence of malignancy. We therefore compared non-
transformed human breast epithelial cell lines (HMECs
(HME I, HME II), MCF10A and MCF10F) with reduc-
tion mammoplasty tissues for cell surface and molecular
features. Surprisingly, we found that under serum-free
conditions none of the normal human mammary epithe-
lial cell lines contained Luminal 1 cells in culture, nor
could they be classified as Luminal 2 cells. Rather nor-
mal human breast epithelial cell lines were classified
into two categories: Basal lines (HME I and MCF10F
cell lines) that contained a prominent Basal population,
and Mesenchymal lines (HME II and MCF10A cell
lines) that were comprised of a majority (> 90%)
Mesenchymal EpCAM
-/CD24
-/CD49f
+ cells (Figure 6a).
These data indicate that the selection for basal and
mesenchymal cell states in cu l t u r e db r e a s te p i t h e l i a l
cells is not a consequence of genetic mutation or malig-
nant transformation, but is likely the result of adherent
in vitro selection.
We used immunofluorescence to determine whether
non-transformed Basal and Mesenchymal cell lines
expressed similar markers of normal reduction mammo-
plasty counterparts (Figure 6e). In contrast to Mesench-
ymal cancer cell lines, which failed to express CK8/18
or CK14 and grew as spindle cells, normal Mesenchymal
epithelial cell lines expressed both CK14 and vimentin,
and grew as cobblestone islands of cells, suggesting they
retained some of the molecular features of normal
Mesenchymal epithelial cells found in reduction mam-
moplasty tissues. In addition, Basal mammary cell lines
expressed CK8/18 and CK14 but also expressed vimen-
tin, reminiscent of Basal cells in breast tissues. These
data suggest that normal Basal and Mesenchymal cell
lines may retain more features that mirror differentia-
tion in reduction mammoplasty tissues than Basal and
Mesenchymal cells in cancer cell lines.
The expression of CK14, CK8/18, and vimentin com-
bined with the high CD44 expression in HMEC cultures
(data not shown) suggested that Basal and Mesenchymal
cells may retain characteristics of bi-potent progenitor
cells. Mammosphere formation is associated with the
ability to generate cells of both breast lineages in culture
[34]. Therefore, we performed mammosphere assays to
gauge progenitor activity in normal mammary epithelial
cell lines. Indeed, HME I, HME II, MCF10A and
MCF10F cells all formed mammospheres at similar
rates, although MCF10A cells formed much larger
spheres compared to the other lines (Figure 6b, data not
shown). The potential progenitor activity of HMEC
cultures combined with the obvious absence of EpCAM
+/CD24
+/CD49f
- Luminal 1 cells prompted us to deter-
mine whether Basal or Mesenchymal lines could differ-
entiate and give rise to Luminal 1 cells in vitro.I t
has been reported that luminal-type cells are growth-
promoted in the presence of serum while basal/
mesenchymal cells are selected for in the presence of
serum-free media, which is the typical growth medium
for HMECs [35]. Therefore, we treated HME I/II and
MCF10A cell lines with serum and assessed whether
this might affect the differentiation of cells into Luminal
1 cells. The addition of serum to Basal HME I cells
indeed led to the development of a Luminal 2 cell line
due to an increase in the proportion of EpCAM
+/CD24
+/CD49f
+ cells (> 90%) and the loss of EpCAM
+/CD24
-/
CD49f
+ cells (Figure 6c, d). However, the addition of
serum failed to induce differentiation of Luminal 1 cells.
In contrast to Basal lines, the addition of serum to
Mesenchymal lines only resulted in a modest increase in
Luminal 2 cells. However, a significant increase in the
proportion of CD24
+ luminal cells lacking EpCAM
expression was observed in Mesenchymal cell lines.
Since this cell type does not exist in any significant pro-
portion in reduction mammoplasty tissues, it is unclear
what type of luminal cell this is.
The expansion of Luminal 2 cells was confirmed by
immunofluorescence for expression of lineage markers
CK8/18 expression and EpCAM expression (Figure 6e).
Collectively, these results indicate that in vitro
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Page 12 of 17Figure 6 Human breast cell lines are enriched for basal and mesenchymal phenotypes. (a) Normal breast cell lines demonstrate loss of
EpCAM
+/CD49f- and EpCAM
+/CD24
+/CD49f
+ populations compared to primary breast epithelial cells isolated from reduction mammoplasty.
Reduction mammoplasty tissues (RM) and normal breast cells lines as well as matched RM with HME cell lines were stained with EpCAM, CD24
and CD49f and quantified by flow cytometry as described in Materials and methods. (b) Quantification of mammospheres formed in non-
adherent culture by HME II, MCF10A and MCF10F cell lines (left) and representative images (right). Bar = 100 μm. (c, d) Addition of 5% serum to
the culture conditions of HME cells increases differentiation to a more luminal state as assessed by flow cytometry for EpCAM, CD49f and CD24.
Representative dot plots are shown in C and quantification in D. (e) Changes in Basal/Luminal differentiation were assessed by
immunofluorescence staining for CK8/18, EpCAM, CK14 and vimentin following treatment with serum. Cells were counterstained with DAPI
(blue). HME I cells are shown, bar = 100 μm.
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Page 13 of 17cultivation of human breast epithelial cells selects for
the Mesenchymal and Basal cells which retain the capa-
city to differentiate into EpCAM
+/CD24
+/CD49f
+ Lumi-
nal 2 cells or CD24
+ cells.
Discussion
We have used flow cytometry and immunostaining for
lineage markers to identify four epithelial cell states pre-
sent within normal human breast epithelial tissues and
have shown that these cell states can be used to stratify
a panel of human breast cancer cell lines. Through use
of a three-marker strategy, we have subdivided human
breast tissue into Luminal 1 cells, characterized by the
majority of cells having an EpCAM
hiCD24
+CD49f
- pro-
file; Luminal 2 cells, characterized by a majority of
EpCAM
hiCD24
+CD49f
+ cells; Basal cells, characterized
by EpCAM
+/loCD24
-CD49f
+ cells, and Mesenchymal
cells, characterized by EpCAM
-CD24
-CD49f
+ cells. Our
description of four major cell types within breast tissue
is similar to previously published reports describing
epithelial populations through the use of EpCAM and
CD49f staining [11-15]. Notably, Villadsen et al.
described two luminal populations representing lobular
and ductal-oriented luminal cells characterized as
EpCAM
hiCD49f
- and EpCAM
hiCD49f
+, respectively, and
lobular and ductal myoepithelial/basal populations with
EpCAM
lo/-CD49f
+ phenotypes [11].
Recently, several groups have identified breast bi-po-
tent progenitor/stem-like activity in EpCAM
+/hiCD49f
+
populations but also in EpCAM
-/loCD49f
+ populations
[11-15]. These conflicting differences may arise from
use of different fluorescently conjugated antibodies for
flow cytometry and gating strategies. Alternatively, it
could be that human breast tissue may contain two dis-
tinct populations of bi-potent stem/progenitor cells.
Consistent with this notion, ductal (CD24
loCD49f
hi) and
lobular/alveolar (CD24
hiCD49f
lo) progenitors that both
give rise to luminal and myoepithelial cells have been
described in the mouse mammary gland [36,37]. By
using CD24 to further define luminal populations in
human breast tissues, it may be that EpCAM
hi/+/CD24
-/
CD49f
+ and EpCAM
lo/+/CD24
-/CD49f
+ represent the
lobule and ductal progenitors in the human breast.
CD24
+ cells have been previously described to be asso-
ciated with the EpCAM
+CD49f
+ luminal progenitors
[14]. However, we have observed that CD24
+ cells
are found in both the EpCAM
hiCD49f
- and EpCAM
hi-
CD49f
+ populations. It is worth speculating that the use
of CD24 as an additional marker might reveal different
bi-potent potentials of progenitor cells. Indeed, we
found that HMEC lines with bi-potent and differentia-
tion potential contained EpCAM
+/CD24
-/CD49f
+ cells,
while those that were nearly all EpCAM
-/CD49f
+ cells
were only able to differentiate into an EpCAM
-/CD24
+
phenotype which does not exists in human breast tissue.
Therefore, future studies that further define the normal
breast epithelial cell hierarchy using additional markers
will be necessary to fully understand the complex cell
types and differentiation states in human tissues.
In this small study, we surprisingly found that the
majority of human breast cancer tissues exhibited a
EpCAM
+/CD49f
+ luminal epithelial differentiation phe-
notype regardless of their molecular subtype. This is
consistent with immunohistochemistry studies that have
reported that breast cancers largely express luminal
makers despite being of the basal molecular subtype
[38]. We found that in tissues and cell lines, the
EpCAM
+/CD49f
+ phenotype contains both CD24
+ and
CD24
- cells. In reduction mammoplasty tissues, EpCAM
+/CD24
-/CD49f
+ cells exhibited a basal cytokeratin phe-
notype while breast cancer cell lines with a basal-like
phenotype also contained a unique population of
EpCAM
+/CD24
-/CD49f
+ cells. Gene expression profiling
of cell lines that exhibit a large EpCAM
+/CD49f
+ popu-
lation most closely corresponded with the expression
profile of Basal-like breast tumors [14] suggesting that
EpCAM
+/CD49f
+ cells may be the cellular precursors to
both luminal and basal-like tumors. Future studies will
need to be performed to determine if this is indeed the
case.
We found that adherent cultures of normal human
breast epithelial cells and to a lesser extent, cancer cell
lines lead to enrichment of cells that exhibited basal and
mesenchymal differentiation states with limited capacity
to differentiate into fully-committed luminal cells. This
suggests that standard adherent culture may select pre-
ferentially for cells of basal-orientation, or may result in
epigentic loss of luminal differentiation programs.
Data from studies in mouse mammary glands and
human tissues suggest that bi-potent progenitor/stem-
like activity is correlated with the formation of colonies
that contain cells of both luminal and basal lineages,
defined by keratin CK8/18/19 or CK14/5 expression,
respectively. However, since luminal cells are lost fol-
lowing in vitro cultivation, this suggests that bi-potent
progenitor/stem-like activity from luminal cells has not
been well studied. This does not discount the evidence
that mammary stem-like cells have basal characteristics
but it does suggest that in vitro methods need to be
improved to allow for maintenance or cultivation of
cells of the luminal lineage to better model cells that are
likely of great importance for human breast tumor
development.
In this study, we found that the morphology and
molecular classification of several cell lines differed from
t h o s ep r e v i o u s l yr e p o r t e db yo t h e r s[ 7 , 4 0 , 4 1 ] .I nt h i s
study, all the commercially available cell lines were
obtained directly from ATCC or from Dr. Ethier, were
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Page 14 of 17characterized at low passage (less than 10 passages) and
were grown in specified medium. Under these condi-
tions, we found a strong association between epithelial
or spindle-cell morphology, marker expression (CK14,
CK18, vimentin, and EpCAM), and the proportion of
CD44
+/CD24
- cells. It is well established that cancer cell
lines evolve over time in culture and may be influenced
by a variety of factors including confluency, media com-
positions as well as passage number. Thus, it is highly
likely that as certain cell lines have evolved in culture
when grown under differing conditions and in turn have
acquired different morphological features. However, it is
likely the case that such cell lines could still be classified
on the basis of cell surface phenotypes and be grouped
into one of the four breast epithelial differentiation
states. Future studies will be needed to determine
whether the plasticity of the cell state dynamics within
cancer cell lines is due to de novo acquired mutations or
due to epigenetic changes associated with extracellular
environment.
Conclusions
Our data indicate that, while cell lines as a group indeed
represent the heterogeneity of human breast tumors,
individually, they exhibit a notable increase in lineage-
restricted profiles that falls short of truly representing
the intratumoral heterogeneity of individual breast
tumors, regardless of their molecular classification. This
is in large part due to the loss of Luminal 1 cells in cul-
ture, which represents a major cell phenotype of normal
and malignant breast tissues. Additionally, we found
that normal human breast epithelial cell lines, like can-
cer cell lines, have a Basal/Mesenchymal-restricted line-
age phenotype under normal serum-free culture
conditions but that they can be induced to partially dif-
ferentiate under serum-containing conditions. However,
the four normal breast cell lines tested, representing
some of the most commonly used cell lines for studying
the behavior of mammary epithelial cells in culture,
have a phenotype that does not represent the major cell
types within breast tissue, namely, differentiated luminal
epithelial cells and luminally-oriented progenitors. These
results serve as a resource for further understanding the
behavior and origins of breast cell lines, which are cru-
cial and widely used research models. However, they
also demonstrate that additional models and cell lines
are needed to more accurately depict and study human
breast epithelial cell types and tumors in a manner that
is more efficient for developing effective therapies.
These findings also indicate that further studies are
needed to identify culture conditions that can allow for
the growth and expansion of Luminal 1 cells, which
seem to be unable to survive or expand in vitro.
Additional material
Additional file 1: Morphology and surface markers EpCAM, CD24,
and CD49f classify breast cancer cell lines into distinct
differentiation states. Human Luminal breast cancer cell lines can be
classified into Luminal 1 or Luminal 2 cell lines based on morphology in
tissue culture (left panels, original magnification: 100×) and by expression
of EpCAM, CD24 and CD49f cell surface markers (dot plots, right panels).
Cell lines were stained for EpCAM, CD24, and CD49f and quantified by
flow cytometry as described in Materials and methods.
Additional file 2: Morphology and surface markers EpCAM, CD24,
and CD49f classify breast cancer cell lines into distinct
differentiation states. Human Basal breast cancer cell lines can be
classified into Basal or Mesenchymal cell lines based on morphology in
tissue culture (left panels, original magnification: 100×) and by expression
of EpCAM, CD24 and CD49f cell surface markers (dot plots, right panels).
Cell lines were stained for EpCAM, CD24, and CD49f and quantified by
flow cytometry as described in Materials and Methods.
Additional file 3: CD44
+/CD24
-/EpCAM
+ cells are variable across a
panel of cultured human breast cell lines. Human breast cancer cell
lines were stained for EpCAM, CD24, and CD44 and quantified by flow
cytometry as described in Materials and Methods. Cell staining CD44
+/CD24
- (upper left quadrant, dot plots) were analyzed for the
percentage of EpCAM
+ cells, which is shown in the histogram to the
right of the dot plots. The percentage of CD44
+/CD24
-/EpCAM
+ cells is
calculated by multiplying the percentage of EpCAM
+ cells by the
percentage of CD44
+/CD24
+ cells.
Additional file 4: Luminal 1, Luminal 2, Basal, and Mesenchymal cell
lines identified by EpCAM, CD24, and CD49f expression were
classified on the basis of CK14, CK8/18, ERa, EpCAM, and vimentin
expression. Representative immunofluorescent images are from the
panel of Luminal 1, Luminal 2, Basal, and Mesenchymal cell lines. Nuclei
were counterstained with DAPI (blue). Original magnification: 200×.
Additional file 5: Table 1. Molecular and cellular characterization of
human breast cell lines.
Additional file 6: Table 2. Histopathological characteristics of breast
cancer cell line xenografts.
Additional file 7: Table 3. In vitro vs. in vivo comparative molecular
marker expression of breast cancer cell lines.
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